The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial.

@article{Modest2012TheIO,
  title={The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial.},
  author={Dominik Paul Modest and Andreas Jung and Nicolas Moosmann and Ruediger Paul Laubender and Clemens Albrecht Giessen and Christoph Schulz and Michael Haas and Jennifer Neumann and Stefan Hubert Boeck and Thomas W. Kirchner and Volker Heinemann and Sebastian Stintzing},
  journal={International journal of cancer},
  year={2012},
  volume={131 4},
  pages={980-6}
}
Our study investigated the impact of specific KRAS mutations and BRAF mutation on progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated within the AIO KRK-0104-trial as first-line therapy. In total, 146 (of 185) patients were included in this analysis. Seventy-nine patients presented with KRAS/BRAF wild-type (wt), 41 patients with a KRAS codon 12 and nine patients with a KRAS codon 13 mutation. Seventeen patients presented a BRAF… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

results of C an ce r T he ra py 6 Analysis of the AIO KRK-0104-trial Int

  • TS Maughan, RA Adams, +10 authors cancer et al. Addition of cetuximab to oxaliplatin-based colorectal
  • J. Cancer: 000, 000–000
  • 2011
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…